Jazz Pharmaceuticals Wins FDA Approval for Ziihera Regimens in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals (NASDAQ:JAZZ) has secured FDA approval for two Ziihera-containing regimens in first-line HER2-positive advanced gastroesophageal adenocarcinoma, expanding the drug into an earlier treatment setting after Phase 3 data showed improvements in progression-free and overall survival.

Key Investor Takeaways

• The FDA approved Ziihera plus tislelizumab and chemotherapy for first-line treatment of HER2+ advanced GEA patients with IHC 3+ or IHC 2+/ISH+ disease, regardless of PD-L1 status.
• Jazz Pharmaceuticals (NASDAQ:JAZZ) also received approval for Ziihera plus chemotherapy in HER2+ IHC 3+ patients.
• Phase 3 HERIZON-GEA-01 data showed Ziihera plus tislelizumab and chemotherapy reduced the risk of death by 28% versus trastuzumab plus chemotherapy.
• Median overall survival reached 26.4 months with the three-drug regimen compared with 19.2 months for the comparator.
• The FDA approval broadens Ziihera’s clinical role and gives Jazz an approved first-line treatment option across the HER2+ advanced GEA population specified for the combination regimen.

Why JAZZ Stock Is in Focus

The Ziihera FDA approval gives Jazz two new first-line regimens for adults with unresectable locally advanced or metastatic HER2+ gastroesophageal adenocarcinoma.

Ziihera combined with Tevimbra, or tislelizumab-jsgr, and fluoropyrimidine- and platinum-containing chemotherapy is approved for HER2+ IHC 3+ and IHC 2+/ISH+ disease. Ziihera plus chemotherapy without tislelizumab is approved for patients with HER2+ IHC 3+ disease.

The decision was supported by the ongoing Phase 3 HERIZON-GEA-01 trial. Both Ziihera-containing combinations reduced the risk of disease progression or death by 35% in the overall HER2+ population, with median progression-free survival of 12.4 months versus 8.1 months for trastuzumab plus chemotherapy.

For the Ziihera, tislelizumab and chemotherapy combination, median overall survival was 26.4 months compared with 19.2 months for trastuzumab plus chemotherapy. Jazz said outcomes were generally consistent across major prespecified subgroups, including PD-L1 status and geographic region.

Why This Matters for Investors

Moving Ziihera into first-line HER2+ advanced GEA represents an important expansion of the drug’s treatment opportunity because it places the therapy at the beginning of systemic treatment for eligible patients.

The breadth of the approval is also notable. The Ziihera-tislelizumab-chemotherapy regimen can be used in the specified HER2+ population regardless of PD-L1 status, potentially widening its relevance compared with an approach dependent on PD-L1 selection.

The Phase 3 survival data provide the clinical foundation for that positioning. A greater than seven-month difference in median overall survival versus trastuzumab plus chemotherapy could support the treatment’s competitive profile, although future adoption will ultimately determine the commercial significance for Jazz.

Safety will remain part of that equation. Jazz described the Ziihera-containing regimens as having a manageable safety profile consistent with previous zanidatamab studies. Diarrhea was the most common adverse reaction, with prophylaxis and treatment modifications used to manage the side effect.

What to Watch Next

Jazz is hosting an investor webcast on August 25 to discuss the FDA approval and provide further updates on the zanidatamab development programme.

Investors can also watch for additional analyses from the ongoing HERIZON-GEA-01 trial and for indications of how the newly approved first-line regimens are positioned following their U.S. approval.

Jazz Pharmaceuticals stock price